Navigation Links
Abbott Completes Acquisition of STARLIMS Technologies

ABBOTT PARK, Ill., March 22 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) announced today that it has completed its $123 million acquisition of STARLIMS Technologies Ltd., a leader in laboratory information management systems.  

The acquisition provides Abbott with leading products and expertise to build its position in laboratory informatics, an emerging and rapidly growing field focused on helping to manage the increasing amount of data generated in laboratories. STARLIMS's advanced web-based software applications help laboratories efficiently store, retrieve and analyze data and are designed for a wide variety of laboratory environments operating across a number of scientific, industrial and clinical disciplines.  

"STARLIMS gives us access to innovative technologies and technical expertise for our long-term strategy in laboratory informatics," said Edward L. Michael, executive vice president, diagnostics products, Abbott. "The acquisition enables us to provide a common informatics framework across all of our diagnostics businesses and, equally important, will help accelerate STARLIMS's growth strategy in the non-diagnostics market segments it currently serves."

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs approximately 83,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at

Abbott Forward Looking Statement

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors," to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2009, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments.


Back to top



Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Abbott Announces Positive Data From ABSORB Trial on Its Bioresorbable Vascular Scaffold Technology
2. Abbott Statement: ACCORD Lipid Results Support Treatment Guidelines for Fibrate Use
3. New Data Demonstrates Abbotts Investigational MitraClip(R) System Has Potential to be a Valuable Treatment Option for Patients With Mitral Regurgitation, the Most Common Heart Valve Condition
4. Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer
5. Abbott to Collaborate With GSK on Molecular Diagnostic Test to Select Candidate Patients for Future Skin Cancer Immunotherapy
6. Abbott to Present at Cowen and Company Annual Health Care Conference
7. Abbott Receives U.S. FDA Approval for Heat-Stable Norvir(R) (ritonavir) Tablets
8. Abbott Submits New Automated Ovarian Cancer Test for U.S. Approval
9. Abbott and Pierre Fabre SA Announce Collaboration to Research and Develop Novel Treatments for Cancer
10. Abbotts Ibis Technology Named One of the Top Innovations for 2009 by The Scientist
11. The Deal Names Abbott Top Dealmaker for Second Consecutive Year
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 ... addition of the "2016 Future Horizons ... of Abuse Testing Market: Supplier Shares, Country ... report to their offering. --> ... the "2016 Future Horizons and Growth ...
(Date:11/26/2015)... 26, 2015 ... of the  "2016 Future Horizons and ... Drug Monitoring (TDM) Market: Supplier Shares, ... Opportunities"  report to their offering.  ... the addition of the  "2016 Future ...
(Date:11/26/2015)... Nov. 26, 2015 Research and Markets ... the "2016 Future Horizons and Growth Strategies ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Emerging ... --> --> This ... the Italian therapeutic drug monitoring market, including emerging ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... 2015 , ... The Catalent Applied Drug Delivery Institute today ... dose form selection in early phase drug development. The first of these is ... together the UK’s emerging life sciences companies, corporate partners, and investors, at Milton ...
(Date:11/26/2015)... ... November 26, 2015 , ... PRMA Plastic Surgery is updating ... our surgeons performed their 6,000th free flap breast reconstruction surgery! , “What an accomplishment ... day excited to rebuild lives and it’s an honor to have served all of ...
(Date:11/26/2015)... ... 26, 2015 , ... Pixel Film Studios brings Final Cut ... Vintage. This newly styled ProTrailer pack comes with 30 all-new vintage-inspired designs, with ... users limitless opportunities to stylize and create designs quickly and easily, all within ...
(Date:11/26/2015)... , ... November 26, 2015 , ... Indosoft Inc., developer ... of an application server to improve system efficiency and reliability. , The new Q-Suite ... of these standards, the system avoids locking itself into a specific piece of software ...
(Date:11/25/2015)... ... November 25, 2015 , ... As part of a global ... attracts volunteers together who want to combine talents and resources to help create ... the process. The non-profit launched its first major fundraiser on November 6, 2015 ...
Breaking Medicine News(10 mins):